netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.08  Expand sub section  Anticoagulants and protamine
Idarucizumab (Praxbind)
View adult BNF View SPC online
Formulary
Red
2.5g/50ml solution for injection/infusion

Limited to haematology use and kept under the control of haematology (location = ED) 
   
02.08.01  Expand sub section  Parenteral anticoagulants
Argatroban monohydrate
View adult BNF View SPC online
Formulary
Red

Infusion vial: 250mg/2.5 mL 

 
   
Epoprostenol
View adult BNF View SPC online
Formulary
Red

Infusion vial: 500 micrograms

 
   
02.08.01  Expand sub section  Heparin
Heparin
View adult BNF View SPC online
Formulary Injection (ampoule); 1,000 units/1ml, 5,000 units/5ml, 10,000 units/10ml, 20,000 units/20ml 
   
Heparin
View adult BNF View SPC online
Formulary
Red

unlicensed unlicensed Heparin 500 Units in sodium chloride 0.9% 500 mL infusion bag

 
   
02.08.01  Expand sub section  Low molecular weight heparins
Dalteparin
View adult BNF View SPC online
First Choice Injection: (pre-filled syringe): 2,500 units/0.2ml, 5,000 units/0.2ml, 7,500 units/0.3ml, 10,000/0.4ml, 12,500 units/0.5ml, 15,000 units/0.6ml, 18,000 units/0.72ml 
Enoxaparin
View adult BNF View SPC online
Alternatives Injection (pre-filled syringe): 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 300mg/3ml, 120mg/0.8ml, 150mg/1ml 
   
02.08.01  Expand sub section  Heparinoids to top
Danaparoid sodium
View adult BNF View SPC online
Formulary
Red
Injection (ampoule): 750 units/0.6ml 
   
02.08.01  Expand sub section  Hirudins
Bivalirudin
View adult BNF View SPC online
Formulary
Red
Injection: 250 mg 
Link  NICE CG94: Unstable angina and NSTEMI
Link  NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
   
02.08.01  Expand sub section  Heparin flushes
Heparin (for flushing)
View adult BNF View SPC online
Alternatives Injection: 50 units/5ml, 200 units/2ml 
   
02.08.01  Expand sub section  Fondaparinux
Fondaparinux
View adult BNF View SPC online
Formulary
Red
Injection (pre-filled syringe): 2.5mg/0.5ml 
   
02.08.02  Expand sub section  Oral anticoagulants
Apixaban
(An option in a managed pathway)
View adult BNF View SPC online
Formulary Tablets: 2.5mg, 5mg 
Link  NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery
Link  NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Link  NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
   
Dabigatran
(An option in a managed pathway)
View adult BNF View SPC online
Formulary Capsules: 75mg, 110mg, 150mg 
Link  NICE TA157: Venous thromboembolism - dabigatran
Link  NICE TA249: Dabigatran for Stroke prevention in AF
Link  NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
   
Edoxaban
(An option in a managed pathway)
View adult BNF View SPC online
Formulary

Tablets: 15mg, 30mg, 60mg

 
Link  NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Link  NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
   
Rivaroxaban
(An option in a managed pathway)
View adult BNF View SPC online
Formulary Tablets: 10mg, 15mg, 20mg 
Link  NICE TA256: Rivaroxaban for AF
Link  NICE TA261: Rivaroxaban for treatment of DVT
Link  NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
Link  NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
   
Warfarin
View adult BNF View SPC online
Formulary Tablets: 500mcg, 1mg, 3mg, 5mg 
   
02.08.03  Expand sub section  Protamine sulphate to top
Protamine Sulphate
View adult BNF View SPC online
Formulary
Red
Injection: 50mg/5ml
 
   
 ....
 Non Formulary Items
Acenocoumarol  (Sinthrome)

View adult BNF View SPC online
Non Formulary
 
Bemiparin

View adult BNF View SPC online
Non Formulary
 
Burinex K

View adult BNF View SPC online
Non Formulary
 
Canusal

View adult BNF View SPC online
Non Formulary
 
Centyl K

View adult BNF View SPC online
Non Formulary
 
Diumide-K Continus

View adult BNF View SPC online
Non Formulary
 
Hepsal

View adult BNF View SPC online
Non Formulary
 
Lasikal

View adult BNF View SPC online
Non Formulary
 
Lepirudin

View adult BNF View SPC online
Non Formulary
 
Neo-NaClex-K

View adult BNF View SPC online
Non Formulary
 
Phenindione

View adult BNF View SPC online
Non Formulary
 
Tinzaparin

View adult BNF View SPC online
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use or use by a specialist within specialist centre only. Initiation and monitoring of treatment should remain under the total responsibility of the appropriate hospital clinician or specialist. These drugs should only be prescribed under the direct supervision of that clinician or specialist and are not suitable for shared care arrangements. The drug should be supplied via the hospital or specialist centre for the duration of treatment.   

Amber

These are specialist drugs which must be initiated by secondary care specialist prescribers, but with the potential to transfer prescribing to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care. For these drugs, in order to ensure patient safety, some aspects of care must remain with the specialist due to their complexity e.g. monitoring of disease or drug response. Other more routine aspects can be transferred to the GP e.g. monitoring of adverse effects and supply of the medicine. The specific responsibilities of the specialist and GP are defined in the shared care agreement for each drug. Shared care agreements are still under development for some amber drugs. Until these are available, it would be expected that any shared care request from secondary care to a GP would be accompanied by written information which defines prescribing and monitoring responsibilities. The hospital specialist should also provide the GP with enough information and support to allow the safe transfer and ongoing management of prescribing into primary care.   

Green +

Drugs which should usually be initiated in secondary care, or by a specialist clinician, but can be safely maintained in primary care with very little or no monitoring required. In some cases there may be a further restriction for use outlined - these will be defined in each case.  

Green

These are defined as new and established drugs, which may be prescribed, initiated, changed or maintained on FP10 by the GP and, if appropriate, discontinued without recourse to secondary care. N.B. DRUGS NOT IDENTIFIED IN THE FORMULARY BY A RED, AMBER OR GREEN+ SYMBOL ARE CLASSIFIED AS GREEN.   

netFormulary